LONG TERM FOLLOW-UP ON EFFECTIVENESS AND SAFETY OF ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS

Treatment of juvenile idiopathic arthritis (JIA) is one of the most complex and urgent problems of rheumatology. Objective: We undertook a study to evaluate the effectiveness and safety of long-term therapy with etanercept in patients with JIA without systemic manifestations. Methods and patients: Patients in the study were divided into 2 groups. Patients of the main group (n = 197) received etanercept, the comparison group (n = 200) - methotrexate. The effectiveness was assessed by the American College of Rheumatology (ACR) criteria and Wallace's criteria for clinical remission (CR) and the 4-year JADAS71 index. Results: We included 397 patients with JIA. In 6 months and 12 months a remission of articular syndrome was detected in 72 and 53 patients respectively; 83% and 65% of patients receiving etanercert and methotrexate, respectively. Laboratory indicators of disease activity corresponded with reference values in 91 and 48% in a period of 6 months, in 12 months - in 94 and 68% of patients. According to the results of Childhood Health Assessment Questionnaire (CHAQ) functional activity fully recovered in 65 and 79%; 30 and 58% of children in a period of 6 and 12 months of follow-up. Within 1 month improvement according to ACR pedi criteria 30/50/70 was achieved in 79/62/34% of patients treated by genetically engineered biological agents. After 6 months AKRpedi criteria 30/50/70 was achieved in 97/96/89% and 63/57/47% against the background of therapy with etanercept and methotrexate, respectively. Etanercept induced inactive stage of the disease / remission [6 (4, 9) and 12 (6, 18) months; p <0,0001, respectively] in significantly shorter time than methotrexate. Within 6 and 12 months of follow up inactive stage of the disease / remission was reported in 30 and 49% of patients treated with inhibitor etanercept, and 9 and 38% of patients receiving methotrexate. Disease activity index JADAS71 in children treated with etanercept was significantly lower than in patients treated with methotrexate for 1 year. Conclusion: Etanercept has a significantly faster and more pronounced anti-inflammatory effect than the classic immunosuppressant methotrexate.

1. Baranov A.A. Pediatriya. Klinicheskie rekomendatsii [Pediatrics. Clinical Guidelines]. Moscow, GEOTAR-Media, 2009. P. 387–420.

2. Borchers A.T., Selmi C., Cheema G., Keen C.L., Shoenfeld Y., Gershwin M.E. Juvenile idiopathic arthritis. Autoimmun. Rev. 2006; 5: 279–298.

3. Cassidy J.T., Petty R.E., Laxer R.M. et al. Textbook of pediatric rheumatology. 6th edn. Philadelphia: Saunders Elsevier. 2010. 794 p.

4. Bowyer S.L., Roettcher P.A., Higgins G.C., Adams B., Myers L.K., Wallace C. et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J. Rheumatol. 2003; 30: 394–400.

5. Barrera P., Th. Boerbooms A.M., Janssen E.M. et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and interleukin 6 levels in rheumatoid arthritis. Arthritis Rheum. 1993; 36: 1070–1079.

6. Brewer E.J., Bass J., Baum J., Cassidy J.T., Fink C., Jacobs J. et al. Current proposed revision of JRA criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum. 1977; 20 (Suppl.): 195–199.

7. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Exp. Opin. Biol. Ther. 2013; 13 (3): 361–376.

8. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (57): 16–21.

9. Di Diovini F., Nuki G., Duff G. Tumor necrosis factor in synovial exudates. Ann. Rheum. Dis. 1988; 47: 768–772.

10. Hyrich K.L., Silman A.J., Watson K.D., Symmons D.P.M. Anti-tumor necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 2004; 63 (12): 1538–1543.

11. Woo P., Wedderburn L.R. Juvenile chronic arthritis. Lancet. 1998; 351: 969–973.

12. Wallace C.A., Giannini E.H., Spalding S.J., Hashkes P.J., O’Neil K.M., Zeft A.S., Szer I.S., Ringold S., Brunner H.I., Schanberg L.E., Sundel R.P., Milojevic D., Punaro M.G., Chira P., Gottlieb B.S., Higgins G.C., Ilowite N.T., Kimura Y., Hamilton S., Johnson A., Huang B., Lovell D.J. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012; 64 (6): 2012–2021.

13. Papsdorf V., Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011; 50: 214–221.

14. Singh J.A., Furst D.E., Bharat A. et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2012; 64: 625–639.

15. Alekseeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Ruk-vo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Pod obshch. red. A.A. Baranova [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Algorithms for Diagnosis and Treatment. Guideline for Doctors, Teachers, Scientists. Edited by A.A. Baranov]. Moscow, VEDI, 2007. 368 p.

16. Alexeeva E.I., Baranov A.A. Rukovodstvo po biologicheskoi terapii [Guideline in Biological Therapy]. Moscow, 2011.

17. Perez-Alvarez R., Perez-de-Lis M., Ramos-Casals M. Biologics-induced autoimmune diseases. Curr. Opin. Rheum. 2013; 25 (1): 56–64.

18. Ungar W.J., Costa V., Burnett H.F. et al. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013; 42: 597–618.

19. Stoll M.L., Cron R.Q. Treatment of juvenile idiopathic arthritis: a revolution in care. Stoll and Cron Pediatric Rheumatology. 2014; 12: 13. Doi:10.1186/1546-0096-12-13 http://www.ped-rheum.com/content/12/1/13.

20. Otten M.H., Anink J., Spronk S., van Suijlekom-Smit L.W. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann. Rheum. Dis. 2013; 72 (11): 1806–1812.

21. Horneff G., Foeldvari I., Minden K. et al. 10 years experience in the German JIA Etanercept Registry — lessons from changing patient populations. Arthritis Rheum. (Munich). 2011; 31: 334–342.

22. Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of Juvenile Idiopathic Arthritis (JIA). Ann. Rheum. Dis. 2004; 63: 1638–1644.

23. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2009; 68 (4): 519–525.

24. Giannini E.H., Ilowite N.T., Lovell D.J. et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60 (9): 2794–2804.

25. Punzi L., Furlan A., Podswiadek M., Gava A., Valente M., De Marchi M. et al. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun. Rev. 2009; 8: 228–232.

26. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. Doi: 10.1007/s00431-010-1238-z.

27. Hayward K., Wallace C. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis. Res. Ther. 2009; 11: 216. Doi: 10.1186/ar2619.

28. Pain C., McCann L. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy. 2009; 3: 127–139.

29. Horneff G., Ruperto N., Burgos-Vargas R. et al. Effectiveness and safety of etanercept in paediatric subjects with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: the clipper study. Ann. Rheum. Dis. 2012; 71 (Suppl.): 424.

30. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Whitmore J., Finck B.K. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000, 342 (11): 763–769.

31. Lovell D.J., Reiff A., Ilowite N.T. et al; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.

32. Quartier P., Taupin P., Bourdeault F. et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the other onset type. Arthritis Rheum. 2003; 48: 1093–1101.

33. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with Juvenile Idiopathic Arthritis (JIA). Preliminary data from the German JIA registry. Ann. Rheum. Dis. 2009; 68 (4): 519–525.

34. Kietz D.A., Pepmueller P.H., Moore T.L. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J. Rheumatol. 2001; 28: 360–362.

35. Pchelintseva A.O., Panasyuk E.Yu., Ryabitseva O.F. The effectiveness of etanercept in patients with rheumatoid arthritis (the results of a multicenter study Russian standard). Nauchno-prakticheskaya revmatologiya = Science-practical rheumatology.. 2013; 51 (6): 639–645.

36. Otten M., Prince F., Twilt M. et al. Delaed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol. 2010; 37: 665–667.

37. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C., et al. Long-term efficacy and safety of etanercept in children with polyarticular - course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003; 48: 218–226.

38. Valieva S.I. Novye tekhnologii v lechenii sistemnogo yuvenil'nogo idiopaticheskogo artrita. Avtoref. dis. ... dokt. med. nauk [New technologies in the treatment of systemic juvenile idiopathic arthritis. Author’s abstract]. Moscow, 2014. 48 p.

39. Nielsen S., Ruperto N., Gerloni V., Simonini G. et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin. Exp. Rheum. 2008; 26 (4): 688–692.

40. Lovell D.J., Reiff A., Jones O.Y. et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006; 54: 1987–1994.

41. Sigidin Ya.A., Lukina G.V. Etanercept in modern rheumatology. Nauchno-prakticheskaya revmatologiya = Science-practical rheumatology. 2010; 3: 78–82.

42. Tubach F., Salmon D., Ravaud P. et al. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 52.